SCHEMBL13533556

SCHEMBL13533556

COc1ccc(S(=O)(=O)Cl)cc1-c1nn2c(C)nc(C)c2c(=O)[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 17/20 0.54
PDE1A P54750 9/20 0.54
PDE1B Q01064 9/20 0.54
PDE1C Q14123 9/20 0.54
PDE4B Q07343 2/20 0.47
PDE6A P16499 2/20 0.46
PDE2A O00408 1/20 0.46
PDE6D O43924 1/20 0.46
PDE9A O76083 1/20 0.46
CHRM2 P08172 1/20 0.46
ADORA3 P0DMS8 1/20 0.46
PDE6G P18545 1/20 0.46
MAOA P21397 1/20 0.46
PDE4A P27815 1/20 0.46
ADORA1 P30542 1/20 0.46
ADRA1A P35348 1/20 0.46
PDE6B P35913 1/20 0.46
PDE6C P51160 1/20 0.46
SLC6A3 Q01959 1/20 0.46
PDE4C Q08493 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL973746 0.89 PDE5A (0.68) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL13533558 0.80 PDE5A (0.77) PDE5APDE1APDE1BPDE1C
SCHEMBL7389060 0.79 PDE5A (0.68) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL28890957 0.79 PDE5A (0.73) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL5307 0.78 PDE5A (0.75) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL29655362 0.78 PDE5A (0.75) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL974554 0.77 PDE5A (0.66) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL6333779 0.77 PDE5A (0.57) PDE5APDE1APDE1BPDE1CPDE4B
SCHEMBL6291389 0.77 PDE5A (0.59) PDE5APDE1APDE1BPDE1CPDE2A
SCHEMBL6287006 0.77 PDE5A (0.53) PDE5APDE1APDE1BPDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016323-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-01-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016323-A1 2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS PDE3A, PDE2A, PDE3B PDE5A 4/4885PDE1A 18/4885PDE1B 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.